Moat
8.0/10
BD combines regulated medical-device manufacturing, hospital relationships, broad installed workflows, and recurring consumables, which creates high switching and qualification costs.
BDXQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 226-250.
Becton Dickinson
Becton Dickinson is a medical technology company that makes medical devices, laboratory products, diagnostic systems, and medication management platforms for hospitals, laboratories, and health systems.
Metadata
Where this company sits
- Ticker
- BDX
- Rank snapshot
- ≈ 240
- Sector
- Health Care
- Industry
- Pharma & MedTech
- Region
- United States
- Index
- S&P 500 · Top 250 by market cap
Metrics
Scoring view
Every metric is paired with a short rationale. The numbers are deliberate, not divine.
Decentralizability
3.0/10
Sterile medical consumables and dispensing hardware are hard to decentralize, but inventory software, workflow coordination, and selected non-critical hardware modules have some open-system potential.
Profitability
6.0/10
BD reported profitable fiscal 2025 operations with about $1.7 billion of net income on about $21.8 billion of revenue, but margins are not software-platform-like.
Price / Earnings
37.4x
Macrotrends listed a late-May 2026 BDX P/E ratio around 37, while its page also showed conflicting current-summary values; this should be treated as market-data dependent.
Market cap
$40.7B
CompaniesMarketCap reported Becton Dickinson market capitalization of about $40.67 billion as of May 2026.
Freed-up capital potential
$3.5B
Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.
Narrative
Why the company matters
A short editorial overview plus the current thesis on moat strength and decentralization pressure.
Business Mix
BD operates across medical devices, diagnostics, biosciences, medication delivery, medication management, and interventional product lines, with fiscal 2025 revenue of about $21.8 billion.
Its competitive position depends on regulated manufacturing scale, hospital purchasing relationships, clinical workflow integration, installed equipment bases, and a broad consumables catalog.
Registry Relevance
BD is a useful registry case because it combines physical medical consumables such as BD Vacutainer with software-linked hospital infrastructure such as BD Pyxis medication dispensing.
The most credible decentralization pressure is not a simple one-for-one product clone; it is a gradual unbundling of proprietary hardware, inventory software, service contracts, and supply-chain coordination.
Moat reading
BD has a strong moat in regulated medical manufacturing, distribution, hospital procurement, product validation, and embedded clinical workflows. Products such as blood collection systems and automated medication dispensing cabinets operate in environments where safety, compliance, training, and reliability matter as much as unit price.
The moat is weaker where value shifts from proprietary cabinet software or branded consumables toward interoperable inventory data, open workflow tooling, modular hardware, and local serviceability, but the burden of clinical proof remains high.
Decentralization reading
BD's physical consumables are difficult to decentralize quickly because sterile manufacturing, additive chemistry, lot traceability, adverse-event reporting, and regulatory controls are central to safe use.
Medication management systems are more exposed to open and federated alternatives at the software and coordination layer: inventory, lot tracking, medication dispense records, demand planning, and audit trails can be separated from a single proprietary cabinet vendor if hardware interfaces and clinical governance mature.
Products
Where the moat actually touches users
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 3 structured disruption concepts across the current product set.
3 disruption concepts tracked0 documented exceptions
BD Vacutainer
Blood collection consumables
1 conceptBD Vacutainer is BD's blood collection system family, including evacuated tubes, needles, holders, and safety collection sets used in clinical blood draws.
BD Pyxis
Automated medication dispensing and inventory management
2 conceptsBD Pyxis is a medication management platform centered on automated dispensing cabinets and related software for decentralized medication storage, dispensing, and inventory control in healthcare facilities.
Technology waves
Strategic lenses
These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.
Microfactories and automated mini-home production
Small, software-defined manufacturing cells could make localized production less eccentric and more default.
- • Products with heavy branding but generic bill-of-materials profiles look increasingly vulnerable.
- • Logistics moats still matter, but their margin for arrogance should narrow.
- • Open-source production recipes can pressure both price and product differentiation.
Printed electronics and PCB tooling
PCB fabrication, chip packaging, and increasingly automated electronics assembly continue shrinking the distance between prototype and local production.
- • Incumbents with hardware lock-in should be evaluated against a future of much cheaper custom electronics.
- • Pick-and-place automation lowers the coordination cost for distributed manufacturing cells.
- • The most durable hardware moats may migrate toward fabs, ecosystems, and compliance rather than assembly itself.
Paper trail
Visible evidence trail
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Becton Dickinson 2025 Form 10-K
Becton, Dickinson and Company · annual report
Official fiscal 2025 annual report used for revenue, profitability, business mix, and risk context.
Reviewed 2026-06-03
Becton Dickinson Investor Relations
Becton, Dickinson and Company · investor relations
Primary investor portal for BD filings, annual reports, and company financial communications.
Reviewed 2026-06-03
Becton Dickinson Market Capitalization
CompaniesMarketCap · market data
Market capitalization reference for BDX in the May 2026 registry refresh window.
Reviewed 2026-06-03
BD Vacutainer UltraTouch Push Button Blood Collection Set
Becton, Dickinson and Company · product page
BD product page describing a Vacutainer blood collection set and its safety and workflow features.
Reviewed 2026-06-03
BD Pyxis MedStation ES System
Becton, Dickinson and Company · product page
BD product page describing Pyxis MedStation ES as an automated medication dispensing system for decentralized medication management.
Reviewed 2026-06-03